Clinical Trial Update: Tobramycin 300 mg Once-a-day (o.d.) Aerosol in Adults With Cystic Fibrosis [Phase 4]

View source ↗

Summary

This is a Phase 4 clinical trial update for once-daily inhaled tobramycin (300 mg) in adults with cystic fibrosis. The trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• TOBI (Tobramycin inhalation solution)

Snippet

Sponsor: University of Milan | Conditions: Cystic Fibrosis | Phase 4 | Status: COMPLETED